Extended‑release sodium oxybate for children with narcolepsy type 1
Official title: Safety, Convenience, and Tolerability of a Nightly Single Oral Dose of Extended-release Sodium Oxybate in Children
Run by Stanford University · NCT06809803 · Data updated 2026-11-12
This will test whether an extended‑release form of sodium oxybate is safer, more convenient, and preferred by children with narcolepsy type 1 compared with non‑extended‑release oxybate options.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 7 Years to 17 Years |
| Sex | All |
| Enrollment | 36 (estimated) |
| Sponsor | Stanford University Academic / other |
| Locations | 1 site (Redwood City, California) |
| Status | Recruiting |
| Started | October 27, 2025 |
| Main results expected | June 2027 |
| Study ends | July 2027 |
| Registry record updated | November 6, 2025 |
| Trial ID | NCT06809803 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children with a documented diagnosis of narcolepsy type 1 who are under the care of the Stanford Sleep Clinic, are on stable medications, and whose parent/guardian provides consent and the child agrees to participate.
✕Probably not a fit
Patients with uncontrolled mental health or sleep disorders causing sleepiness, current suicidal thoughts or severe depression, active illegal drug use, or current pregnancy are excluded and unlikely to benefit from joining this trial.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 2 interventional trial enrolls children with documented narcolepsy type 1 who are followed at the Stanford Sleep Clinic to compare extended‑release sodium oxybate with non‑extended‑release oxybates. Participants will receive the two treatment approaches and researchers will collect data on patient and parent treatment preference, safety, tolerability, convenience, and symptom response. The trial requires informed parental/guardian consent and stable background medications during participation. Safety monitoring and standardized measures of narcolepsy symptoms and tolerability will be used to compare outcomes between the formulations.
Why it matters
Potential benefit: If successful, the extended‑release option could offer children a more convenient and better tolerated oxybate choice that works as well as current formulations.
How similar studies have gone: Immediate‑release sodium oxybate is an established treatment for narcolepsy and extended‑release formulations have shown positive results in adults, but pediatric data are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Participants must be under the care of a doctor at the Stanford Sleep Clinic. 2. Participants must have a documented diagnosis of narcolepsy type 1 shown by sleepiness and either: a spinal fluid marker for narcolepsy (hypocretin-1) at a specific level, or a history of sudden loss of muscle control (cataplexy), or a particular genetic marker for narcolepsy, or a sleep study showing a specific sleep pattern for narcolepsy. 3. Parent(s), or guardian(s) have signed a consent form and the child must agree to participate. 4. Participants are on a stable dose of medications Exclusion Criteria: Participants who have any of the following conditions will not be included in the study 1. Uncontrolled mental health problems 2. Uncontrolled sleep problems that lead to sleepiness. 3. Currently having thought about ending one's life or sadness or loss of interest 4. Currently having a problem with illegal drug use 5. Currently pregnant
Where it's running
-
Stanford University
Redwood City, California, United States Recruiting
Study contacts
- Principal investigator: Oliver Sum-Ping, MD — Stanford University
- Study coordinator: Miran Cho
- Email: mirancho@stanford.edu
- Phone: 650-724-4149
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Diet changes to reduce sleepiness in narcolepsy and idiopathic hypersomnia
This project will try whether a 12-week whole-food ketogenic diet versus an isocaloric standard whole-food diet reduces daytime sleepiness and improves quality of life in adults with narcolepsy or idiopathic hypersomnia.
-
A digital tool to help decide about an ICD
We’re testing a patient-friendly online aid to help people with advanced heart failure decide whether an implantable cardioverter-defibrillator (ICD) is right for them.
-
Wise Interventions to Boost Pediatric Weight Control
This study tests whether adding two quick social-psychology activities (growth mindset and self-affirmation) to a family-based weight management program helps 10–15 year-olds with obesity achieve better BMI outcomes over 12 months.
-
Reducing Chronic Pain After Cesarean Delivery
A single-session pain-relief class called Empowered Relief is tested alongside standard postpartum care to see if it helps women who have ongoing pain after cesarean delivery.
-
Human-created animated art vs AI-created art: does it change how you feel right away?
This online trial tests whether watching a human-made animated art film or an AI-made one, or doing nothing, quickly changes mood or sense of connection in U.S. adults.
-
SMILE in one eye vs Ray tracing-guided LASIK in the fellow eye
This study tests two laser vision correction methods—SMILE in one eye and ray-tracing guided LASIK in the other eye—to see which provides better vision and quality of life for adults with myopia and astigmatism.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.